PTC Therapeutics Iberia

Company snapshot

PTC es una compañía biofarmacéutica centrada en el paciente y basada en la ciencia, enfocada en descubrir, desarrollar y comercializar medicamentos para pacientes con enfermedades raras y graves. Esta página es para la región de Iberia (España y Portugal) A PTC é uma empresa biofarmacêutica centrada no doente e baseada na ciência, focada em descobrir, desenvolver e comercializar medicamentos para

• 2 active pipeline program(s) linked via ClinicalTrials.gov.
• 2 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for PTC Therapeutics Iberia. Not investment advice.

• What is PTC Therapeutics Iberia?

  PTC Therapeutics International is a pharma organization headquartered in DUBLIN, IE. Primary therapeutic focus areas include Leiomyosarcoma, Friedreich Ataxia. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EM

• Is PTC Therapeutics Iberia publicly traded?

  PTC Therapeutics Iberia appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does PTC Therapeutics Iberia develop or market?

  No drug profiles are currently linked to PTC Therapeutics Iberia. Pipeline programs may still list investigational assets.

• What are the latest developments for PTC Therapeutics Iberia?

  In the last 12 months our linked public records show 2 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does PTC Therapeutics Iberia focus on?

  PTC Therapeutics Iberia focuses on Leiomyosarcoma, Friedreich Ataxia based on our analysis of their pipeline programs and drug development activities.